欢迎访问《现代生物医学进展》编辑部！

目的：观察 ICE 方案 (异环磷酰胺 IFO，卡铂 CBP，依托泊苷 VP-16) 治疗复发 / 难治性非霍奇金弥漫大 B 细胞淋巴瘤（ Non-hodgkin's lymphoma， NHL）的疗效及安全性。方法： 20 例经系统化疗后复发或进展的非霍奇金弥漫大 B 细胞淋巴瘤 (DLBCL)患者，采用 ICE 方案化疗至少 2 周期， IFO 5 g/m2，第 2 天，持续 24 小时静脉输注， CBP 按 AUC=5， max 800 mg，第 2 天，静脉输注,VP-16. 100 mg/m2，第 1 -3 天，静脉输注。结果：完全缓解（ complete response， CR）5 例，部分缓解（ partial response， PR）8 例，疾病稳定（ stable disease， SD）4 例，疾病进展（ progress disease， PD）3 例，总有效率（ overall response rate， ORR， CR+PR）65%，化疗副作用主要为骨髓抑制（ Ⅰ 、Ⅱ 度 6 例， Ⅲ 、Ⅳ 度 14 例），其他不良反应包括胃肠道反应、粘膜损伤、肝肾毒性及脱发等均可耐受。结论： ICE 方案可用于非霍奇金弥漫大 B 细胞淋巴瘤的二线化疗方案。

英文摘要:

Objective:To evaluate the safety and efficacy of the ifosfamide (IFO) combined with carboplatin (CBP) and vepeside (VP-16) in the treatment of patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).Methods:Twenty patients with conformed relapsed or refractory Non-hodgkin's lymphoma (NHL) were enrolled in this study. The chemotheraphy of regimen consisted of IFO(5 g/m2, day 2, continue 24 h), carboplatin(CBP=5, max 800 mg, day 2), and vepeside(1 00 mg/m2, day 1-3).Results:In the twenty cases,the complete response was in 5 cases, the partial response was in 8 cases, 4 cases was no change, 3 cases was progressive, and the oveall reponse rate (CR+PR) was 65%. Side effect of chemotherapy mainly manifest as bone marrow suppression, while other adverse reactions, including gastrointestinal reaction, mucosal injury, liver and kidney toxicity and hair loss, can be tolerated.Conclusion:ICE regimen can achieve a safety result in the treatment of relapsed or refractory non-Hodgkin's lymphoma (NHL), and the toxicity was tolerable

View Full Text View/Add Comment Download reader